Forte is the first clinical trial of IMR-687 in patients with beta-thalassemia and follows the initiation of Ardent Phase 2b clinical trial of IMR-687 in sickle cell disease Forte is the first clinical trial of IMR-687 in patients with beta-thalassemia and follows the initiation of Ardent Phase 2b clinical trial of IMR-687 in sickle cell disease

Follow this link:
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh